[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-343809-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-343809-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","clinically-significant-prostate-cancer-prediction-using-multimodal-deep-learning-with-prostate-specific-antigen-restriction-read-online-free","Clinically Significant Prostate Cancer Prediction Using Multimodal Deep Learning with Prostate-Specific Antigen Restriction - read online free","","Prostate cancer is a clinically heterogeneous disease, requiring reliable identification of clinically significant cases even when prostate-specific antigen (PSA) is low to intermediate. This study assessed a multimodal deep-learning framework using ultrasound-guided prostate biopsy data, focusing on patients with PSA ≤ 20 ng/mL. Among 178 consecutive patients, performance was evaluated with receiver operating characteristic curves and AUC. The integrated model achieved AUC 0.878 without PSA restriction and AUC 0.862 under PSA restriction, supported by imaging data and analysis of representative false-negative and false-positive cases.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/clinically-significant-prostate-cancer-prediction-using-multimodal-deep-learning-with-prostate-specific-antigen-restriction-read-online-free/343809/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/clinically-significant-prostate-cancer-prediction-using-multimodal-deep-learning-with-prostate-specific-antigen-restriction-read-online-free/343809.png","ImageObject",300,407,{"name":42,"@type":43},"Quinn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main goal of the study?","Question",{"text":63,"@type":64},"To predict clinically significant prostate cancer using multimodal deep learning while restricting analysis to patients with PSA ≤ 20 ng/mL.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What data and model approach were used?",{"text":68,"@type":64},"The study used multimodal medical data from ultrasound-guided prostate biopsy and applied deep learning to predict clinically significant cases.",{"name":70,"@type":61,"acceptedAnswer":71},"How was predictive performance evaluated?",{"text":72,"@type":64},"Receiver operating characteristic curves were generated and the corresponding area under the curve (AUC) was calculated.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},343809,1790721405,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},962075114765,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Article  \nClinically Significant Prostate Cancer Prediction Using Multimodal Deep Learning with Prostate-Specific Antigen Restriction  \nHayato Takeda 1,2,†, Jun Akatsuka 1,2,†, Tomonari Kiriyama 3, Yuka Toyama 1, Yasushi Numata 2, Hiromu Morikawa 2, Kotaro Tsutsumi 2, Mami Takadate 1,2,4, Hiroya Hasegawa 1, Hikaru Mikami 1,  \nKotaro Obayashi 1, Yuki Endo 1, Takayuki Takahashi 2,5, Manabu Fukumoto 2, Ryuji Ohashi 6, Akira Shimizu 7, Go Kimura 1,2, Yukihiro Kondo 1,2 and Yoichiro Yamamoto 1,2,4, *  \nCitation: Takeda, H.; Akatsuka, J.; Kiriyama, T.; Toyama, Y.; Numata, Y.; Morikawa, H.; Tsutsumi, K.; Takadate, M.; Hasegawa, H.; Mikami, H.; et al. Clinically Significant Prostate Cancer Prediction Using Multimodal Deep Learning with Prostate-Specific Antigen Restriction. Curr. Oncol. 2024, 31, 7180–7189. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/curroncol31110530](10.3390/curroncol31110530)  \nReceived: 27 September 2024  \nRevised: 7 November 2024  \nAccepted: 13 November 2024  \nPublished: 15 November 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Urology, Nippon Medical School Hospital, Tokyo 113-8603, Japan; [s8053@nms.ac.jp](s8053@nms.ac.jp) (H.T.);  \n[s00-001@nms.ac.jp](s00-001@nms.ac.jp) (J.A.); [s4036@nms.ac.jp](s4036@nms.ac.jp) (Y.T.); [m-taniuchi@nms.ac.jp](m-taniuchi@nms.ac.jp) (M.T.); [h-hasegawa@nms.ac.jp](h-hasegawa@nms.ac.jp) (H.H.);  \n[h-mikami86@nms.ac.jp](h-mikami86@nms.ac.jp) (H.M.); [kotaro-o@nms.ac.jp](kotaro-o@nms.ac.jp) (K.O.); [y-endo1@nms.ac.jp](y-endo1@nms.ac.jp) (Y.E.);  \n[gokimura@nms.ac.jp](gokimura@nms.ac.jp) (G.K.); [kondoy@nms.ac.jp](kondoy@nms.ac.jp) (Y.K.)  \n2 Pathology Informatics Team, RIKEN Center for Advanced Intelligence Project, Tokyo 103-0027, Japan; [yasushi.numata@riken.jp](yasushi.numata@riken.jp) (Y.N.); [hiromu.morikawa@riken.jp](hiromu.morikawa@riken.jp) (H.M.); [ktsutsum@hs.uci.edu](ktsutsum@hs.uci.edu) (K.T.); [takayuki.takahashi@a.riken.jp](takayuki.takahashi@a.riken.jp) (T.T.); [manabu.fukumoto.a8@tohoku.ac.jp](manabu.fukumoto.a8@tohoku.ac.jp) (M.F.)  \n3 Department of Radiology, Nippon Medical School Hospital, Tokyo 113-8603, Japan; [s7026@nms.ac.jp](s7026@nms.ac.jp)  \n4 Mathematical Intelligence for Medicine, Graduate School of Medicine, Tohoku University, Miyagi 980-8575, Japan  \n5 Statistical Genetics Team, RIKEN Center for Advanced Intelligence Project, Tokyo 103-0027, Japan  \n6 Department of Integrated Diagnostic Pathology, Nippon Medical School, Tokyo 113-8603, Japan; [r-ohashi@nms.ac.jp](r-ohashi@nms.ac.jp)  \n7 Department of Analytic Human Pathology, Nippon Medical School, Tokyo 113-8603, Japan; [ashimizu@nms.ac.jp](ashimizu@nms.ac.jp)  \n* [Correspondence: yoichiro.yamamoto@riken.jp](Correspondence: yoichiro.yamamoto@riken.jp); Tel.: +81-3-6225-2482 † These authors contributed equally to this work.  \nAbstract: Prostate cancer (PCa) is a clinically heterogeneous disease. Predicting clinically significant PCa with low–intermediate prostate-specific antigen (PSA), which often includes aggressive cancers, is imperative. This study evaluated the predictive accuracy of deep learning analysis using multimodal medical data focused on clinically significant PCa in patients with PSA ≤ 20 ng/mL. Our cohort study included 178 consecutive patients who underwent ultrasound-guided prostate biopsy. Deep learning analyses were applied to predict clinically significant PCa. We generated receiver operating characteristic curves and calculated the corresponding area under the curve (AUC) to assess the prediction. The AUC of the integrated medical data using our multimodal deep learning approach was 0.878 (95% confidence interval [CI]: 0.772–0.98","cbCaiqFtvaYOuCvc","https://ap.wps.com/l/cbCaiqFtvaYOuCvc","pdf",2355994,"English","# Abstract\n# Keywords\n# Introduction","[{\"question\":\"What is the main goal of the study?\",\"answer\":\"To predict clinically significant prostate cancer using multimodal deep learning while restricting analysis to patients with PSA ≤ 20 ng/mL.\"},{\"question\":\"What data and model approach were used?\",\"answer\":\"The study used multimodal medical data from ultrasound-guided prostate biopsy and applied deep learning to predict clinically significant cases.\"},{\"question\":\"How was predictive performance evaluated?\",\"answer\":\"Receiver operating characteristic curves were generated and the corresponding area under the curve (AUC) was calculated.\"}]","Clinically Significant Prostate Cancer Prediction Using Multimodal Deep Learning with Prostate-Specific Antigen Restriction - read online free | PDF",1790052202,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4257e465889b25905ee59143012eb013.webp",983,1390,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aeac4d9bbe9b47bbbf0359a84bd2741f.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e37acf242189b63e37943ca96fea1cdf.webp",981,1387,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5721bb7cfe9b48056a1e65fb269f504c.webp",980,1385]